Skip to content
Advertisement

This photo provided by AstraZeneca shows a bottle of Lynparza. On Friday, Jan. 12, 2018, the Food and Drug Administration approved AstraZeneca PLC's Lynparza, the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene. (Courtesy of AstraZeneca via AP)

This photo provided by AstraZeneca shows a bottle of Lynparza. On Friday, Jan. 12, 2018, the Food and Drug Administration approved AstraZeneca PLC's Lynparza, the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene. (Courtesy of AstraZeneca via AP)

Featured Photo Galleries